Zydis ODT Provides Better Treatments
Summary: This case study explores the impact of Zydis fast-dissolve formulation for Zelapar (Selegiline anti-Parkinson’s compound) on therapeutic profile and patient preference vs Selegiline in traditional tablets. The study reveals that the Zydis formulation positively influenced the therapeutic profile of Zelapar, resulting in higher patient preference and improved market performance. The case study provides valuable insights into the benefits of Zydis fast-dissolve technology and how it can optimize your product for commercial success.